Development of virus-specific immune responses in SHIVKU-infected macaques treated with PMPA

Virology

Volumn 279, Issue 1, 2001, Pages 97-108

  Kumar, Anil ^a   Buch, Shilpa ^a   Foresman, Larry ^a   Bischofberger, Norbert ^b   Lifson, Jeffrey D ^c   Narayan, Opendra ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b GILEAD SCIENCES   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

AIDS; Antibodies; Antiretroviral treatment; CTL; In vivo animal models; SHIV

Indexed keywords

ANTIRETROVIRUS AGENT; NEUTRALIZING ANTIBODY; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INOCULATION; MACACA; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME; VIREMIA; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALIA; MACACA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0035915990     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0710     Document Type: Article

References (75)

1. The enigma of HIV infection
2. Longitudinal study of HIV-specific cytotoxic lymphocytes in HIV type 1-infected patients: Relative balance between host immune response and the spread of HIV type 1 infection
3. Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice
4. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans
5. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians
6. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors
7. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy
8. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
9. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
10. Cytotoxic T-lymphocyte escape viral variants: How important are they in viral evasion of immune clearance in vivo?
11. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
12. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients
13. Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections
14. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity
15. A model for the maturation of protective antibody responses to SIV envelope proteins in experimentally immunized monkeys
16. AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: Markers with reciprocal predictive value over time after seroconversion
17. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
18. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
19. Neutralizing antibodies administered before but not after virulent SHIV prevent infection in macaques
20. Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status
21. Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production
22. Anti-HIV cellular immunity: Recent advances towards vaccine design
23. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load
24. Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection
25. Characterization of the pathogenic KU-SHIV model of acquired immunodeficiency syndrome in macaques
26. Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques
27. Chimeric SHIV that causes CD4+ T cell loss and AIDS in rhesus macaques
28. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS
29. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus
30. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: Inverse relationship of degree of protection with level of attenuation
31. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy
32. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection
33. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
34. Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection
35. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
36. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: Effect of vaccination on challenge with homologous and heterologous strains of simian human immunodeficiency viruses
37. Use of Herpesvirus saimir-immortalized macaque CD4 T cell clones as stimulators and targets of CTL responses in macaque/AIDS models
38. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition
39. Progress in the development of an HIV-1 vaccine
40. Containment of simian immunodeficiency virus infection: Cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment
41. Control of HIV despite the discontinuation of antiretroviral therapy
42. HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: A viral-suppression-independent mechanism
43. Acquisition of HIV type 1 resistance by beta-chemokine-producing CD4+ T cells
44. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
45. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection
46. Escape of human immunodeficiency virus from immune control
47. Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection
48. Viral dynamics of primary viremia and anti-retroviral therapy in simian immunodeficiency virus infection
49. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
50. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
51. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition
52. Kinetics of immune functions and virus replication during HIV-1 infection
53. Transforming activity and antigenicity of an Epstein - Barr-like virus from lymphoblastoid cell lines of baboons with lymphoid disease
54. A novel enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to HIV-1 envelope glycoproteins based on immobilization of viral glycoproteins in microtiter wells coated with concanavalin A
55. Vigorous HFV-1-specific CD4+ T cell responses associated with control of viremia
56. Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques
57. The immunology of primary HIV infection: Which immune responses control HIV replication?
58. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
59. Pathogenic SHIVKU inoculated into immunized macaques caused infection, but virus burdens progressively declined with time
60. Rebound of HIV-1 viral load after suppression to very low levels
61. Acute effects of pathogenic simian-human immunodeficiency virus challenge on vaccine-induced cellular and humoral immune responses to Gag in rhesus macaques
62. Characterization of immune escape viruses from a macaque immunized with five-virus vaccine and challenged with SHIVKu
63. Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor. (R)-9-(2-phosphonylme-thoxypropyl)adenine
64. Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction
65. Prevention of SIV infection in macaques by (R)-9-(2)-phosphonylmethoxypropyl)adenine
66. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques
67. Early short-term 9-[2-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques
68. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide
69. Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection
70. Early postinfection antiviral treatment reduces viral load and prevents CD4+ cell decline in HIV type 2-infected macaques
71. Frequent detection of escape from cytotoxic T-lymphocyte recognition in perinatal human immunodeficiency virus (HIV) type 1 transmission: The Ariel Project for the prevention of transmission of HIV from mother to infant
72. Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: Effects of viral variation on cytotoxic T-lymphocyte recognition
73. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
74. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy